title: The use of early and midpoint adenoma-carcinoma sequence biomarkers in prediction of neoplastic progression in patients with a history of colorectal neoplasia.
abstract: Since significant neoplasia after initial colonoscopy is low, we conducted this pilot study to compare the predictive role for colorectal neoplasia recurrence of anti-DCC with that of Adnab-9 binding to colonic effluent of high-risk patients. DCC and Adnab-9 effluent ELISA were performed at baseline colonoscopies. The results of follow-up colonoscopies were reviewed. To ensure specificity, immunohistochemistry and Western blot was performed with anti-DCC and for Adnab-9 where optimal fixation times were also evaluated. Mean follow-up was 2.6 years. Of 21 patients, 6 of 10 who progressed to CRN and 2 of 11 who did not had a positive Adnab-9 ELISA result (P=0.08). Despite an initial good correlation with Adnab-9 ELISA results in a smaller dataset, we were unable to obtain consistent subsequent DCC immunohistochemistry or Western blot data using antibody from two different sources. However, the original dataset of Adnab-9 results was reproducible on repetition of the ELISA with a larger set of samples that included this initial dataset and optimal fixation time was 20 min. We conclude that Adnab-9 appears to be a promising prognostic marker for neoplasia in the high-risk population. Industry standards need to be developed for DCC monoclonal antibodies that may have similar utility.
authors.affiliation: Department of Internal Medicine, John D. Dingell VAMC and Wayne State University School of Medicine, Detroit, Michigan, USA.
authors.forename: Hassan
authors.initials: H
authors.lastname: Albataineh
authors.forename: Violeta
authors.initials: V
authors.lastname: Yordanova
authors.forename: Jessica
authors.initials: J
authors.lastname: Bowman
authors.forename: Weili
authors.initials: W
authors.lastname: Zhou
authors.forename: James
authors.initials: J
authors.lastname: Hatfield
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Lawson
authors.forename: Paula
authors.initials: P
authors.lastname: Sochacki
authors.forename: Martin
authors.initials: M
authors.lastname: Tobi
mesh_terms: D000236:Adenoma / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism*; D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000378:metabolism; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D003113:Colonoscopy; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism*; D000075389:DCC Receptor; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000276:immunology / Q000378:metabolism; D010865:Pilot Projects; D011237:Predictive Value of Tests; D011956:Receptors, Cell Surface / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*
chemical_list: C516879:Adnab-9; D000911:Antibodies, Monoclonal; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D000075389:DCC Receptor; C501909:DCC protein, human; D011956:Receptors, Cell Surface; D025521:Tumor Suppressor Proteins